This is the first agreement of its kind for the sleep diagnostic system, the company's strategic business.
WideMed Ltd. (TASE:WDMD) today announced that it is in advanced negotiations to license its Morpheus sleep diagnostic system to a US company. WideMed did not disclose the name of the company, except that it is a public company and a leader in home cardiology testing. No did it disclose any of the terms under negotiations, or the estimated value of the possible contract.
WideMed added that this is the company's first agreement of its kind for its sleep diagnostic system, which is a strategic sector for it.
Morpheus is an US Food and Drug Administration (FDA) approved computer-aided scoring solution for cardio-sleep analysis and data management that provides timely clinical information, enabling the provision of improved patient treatment.
Published by Globes [online], Israel business news - www.globes-online.com - on March 25, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010